

PRESS RELEASE**STALLERGENES APPOINTS NEW CHIEF FINANCIAL OFFICER**

Antony, France, 11 April 2013 – Stallergenes S.A. (Euronext Paris CAC small) today announces the appointment of Peter BUHLER as new Chief Financial Officer and member of the Executive Committee of Stallergenes, as of 15 April 2013.

Peter BUHLER will replace Christian THIRY who has decided, after 12 years with Stallergenes, to take up other projects.

A Swiss national, Peter trained as a Chartered Accountant, complemented by an MBA. He has more than 20 years extensive international experience in Finance, including 12 years in the healthcare industry (Anteis, Merck Serono and Lilly). Since 2010, he was Finance Director Europe for Logitech.

Roberto Gradnik, Chief Executive Officer of Stallergenes, commented: “I would like to thank Christian THIRY who has contributed greatly to the development and quality of Stallergenes’ financial management since 2001. We are delighted to welcome Peter BUHLER, who will support Stallergenes in its future developments.”

ABOUT STALLERGENES

Stallergenes is an international biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using allergen immunotherapy. The leader in sublingual immunotherapy treatment, Stallergenes devotes around 20% of its annual gross sales to Research & Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets.

In 2012, the company generated sales of €240 million, and more than 500,000 patients were treated with Stallergenes products.

Euronext Paris (Compartment B)
CAC small
ISIN: FR0000065674
Reuters: GEN.PA
Bloomberg: GEN.FP



Additional information is available at <http://www.stallergenes.com>

Forward-looking statements related to Stallergenes

This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

<p>Contacts:</p> <p>Roberto Gradnik, Chief Executive Officer Tel. +33 1 55 59 20 04</p> <p>Press Relations</p> <p>Lise Lemonnier, Senior Communication & Public Affairs Director Tel. + 33 1 55 59 20 96 e-mail: llemonnier@stallergenes.com</p>	<p>Investor and press relations agency:</p> <p>FTI Consulting</p> <p>Analyst and investor contact Stéphanie Bia Tel. +33 1 47 03 68 16 stephanie.bia@fticonsulting.com</p> <p>Press contact Emmanuelle Flobert Tel. +33 1 47 03 68 56 emmanuelle.flobert@fticonsulting.com</p>
--	---